J&J gets first approval for multiple myeloma bispecific Tecvayli
pharmaphorum
AUGUST 25, 2022
Teclistamab is a companion bispecific to J&J’s talquetamab, a bispecific antibody that binds to CD3 and GPRC5D, a novel myeloma target. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.
Let's personalize your content